Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
8-K
Termination of a Material Definitive Agreement
2 Feb 24
8-K
Other Events
8 Jan 24
8-K
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
29 Nov 23
8-K
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
9 Nov 23
8-K
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
26 Oct 23
8-K
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
18 Oct 23
8-K
Generation Bio Reports Second Quarter 2023 Financial Results
2 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results
10 May 23
Registration and prospectus
S-8
Registration of securities for employees
6 Mar 24
S-8
Registration of securities for employees
12 Jan 23
POS AM
Prospectus update (post-effective amendment)
24 Feb 22
S-8
Registration of securities for employees
24 Feb 22
POSASR
Automatic shelf registration (post-effective amendment)
24 Feb 22
S-3ASR
Automatic shelf registration
11 Aug 21
S-8
Registration of securities for employees
18 Mar 21
424B4
Prospectus supplement with pricing info
7 Jan 21
S-1MEF
Registration of additional securities for an S-1
6 Jan 21
S-1
IPO registration
4 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
10 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
Other
EFFECT
Notice of effectiveness
10 May 22
EFFECT
Notice of effectiveness
7 Jan 21
CORRESP
Correspondence with SEC
4 Jan 21
CORRESP
Correspondence with SEC
4 Jan 21
UPLOAD
Letter from SEC
23 Dec 20
EFFECT
Notice of effectiveness
12 Jun 20
CERT
Certification of approval for exchange listing
11 Jun 20
CORRESP
Correspondence with SEC
9 Jun 20
CORRESP
Correspondence with SEC
9 Jun 20
CORRESP
Correspondence with SEC
22 May 20
Ownership
4
Matthew Stanton
17 Apr 24
4
Phillip Samayoa
17 Apr 24
4
Antoinette Paone
17 Apr 24
4
Matthew Norkunas
17 Apr 24
4
GEOFF MCDONOUGH
17 Apr 24
4
Yalonda Howze
17 Apr 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
Atlas Venture Fund X, L.P.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24